MedTrace Logo

Manipulating the Gut Microbiome Study

NCT03181828 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2021-12-15

Study results available
· View outcomes & findings →

Summary

The objective is to determine if acetohydroxamic acid (AHA) can prevent hydrolysis of urea by inhibiting the bacterial urease of gut flora of both healthy control adults as well as adults with urea cycle disorders

Conditions

  • Urea Cycle Disorder

Interventions

DRUG

Acetohydroxamic Acid Oral Tablet

A single oral dose of 60 mg/kg acetohydroxamic acid rounded to the nearest 250 mg tablet.

OTHER

No treatment

No treatment

Sponsors & Collaborators

  • Nicholas Ah Mew

    lead OTHER

Principal Investigators

  • Nicholas Ah Mew, MD · Children's National Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-24
Primary Completion
2018-06-05
Completion
2018-06-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03181828 on ClinicalTrials.gov